Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the short term [2][3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Score identifies attractive stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors seeking undervalued stocks [3] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends by analyzing short-term price changes and earnings estimate revisions [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive rating that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with lower ranks (3 Hold, 4 Sell, 5 Strong Sell) should still have favorable Style Scores to mitigate downside risk [11] Company Spotlight: Jazz Pharmaceuticals - Jazz Pharmaceuticals, based in Dublin, is a specialty biopharmaceutical company focusing on neuroscience and oncology, currently rated 2 (Buy) with a VGM Score of A [12] - The company has seen a 2% increase in shares over the past four weeks, with 10 analysts raising earnings estimates for fiscal 2025, leading to a consensus estimate increase of $1.27 to $23.33 per share [12][13] - Jazz Pharmaceuticals has an average earnings surprise of 3.2%, making it a strong candidate for investors [13]